TScan Therapeutics, Inc.TCRXNASDAQ
Loading
Operating Expenses Over TimeStrong
Percentile Rank100
3Y CAGR+21.7%
5Y CAGR+84.6%
Studio
Year-over-Year Change

Expenses from normal business operations (SG&A, R&D, etc.)

3Y CAGR
+21.7%/yr
Annual compound
5Y CAGR
+84.6%/yr
Recent deceleration
Percentile
P100
Near historical high
vs 5Y Ago
21.5x
Strong expansion
Streak
6 yr
Consecutive growthStrong
PeriodValueYoY Change
TTM$144.65M+5.1%
2024$137.64M+20.2%
2023$114.51M+42.8%
2022$80.17M+36.4%
2021$58.78M+772.0%
2020$6.74M+41.4%
2019$4.77M-